news

 

Khaitan & Co has guided India’s second-largest healthcare provider, Manipal Hospitals, on its $168 million acquisition of an 87 percent stake in Kolkata-based hospital chain Medica Synergie from Sheares Healthcare, who were advised by J. Sagar Associates.

The acquisition is in line with Bengaluru-based Manipal Hospitals' strategy of expanding its footprint and presence in Eastern India as the leading hospital chain in the region, the company said in a press release.

The Khaitan team on the deal was led by partners Bharat Anand and Aditya Patni and included counsel Kevin Peter, principal associate Vishakha Singh, senior associate Tushar Bakshi and associate Priyanka Priyadarshini.

Partners Abhinav Rastogi (employment), Gaurav Dasgupta (real estate), Pranjal Prateek (antitrust) and Sachin Bhandawat (trusts) assisted with their subject matter expertise.

The JSA team advising sellers Sheares Healthcare was led by partners Vikram Raghani and Varun Sehgal, and included of counsel Yashvi Singh, and associates Vaishnavi Vyas and Darshin Pareekh. 

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

CAM, WFW act on $185 mln Adani Ports acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas advised its longstanding client Adani on Adani Ports and Special Economic Zone’s acquisition of 80 percent stake in Astro Offshore, an offshore support vessel operator. Watson Farley & Williams advised the selling shareholders of Astro Offshore.

Anagram adds M&A and PE partner from IndusLaw

by Nimitt Dixit |

M&A-focused Anagram Partners has become the latest to turn to IndusLaw to expand its offerings with the addition of M&A and private equity-focused partner Faraz Khan in Mumbai.

Trilegal, Latham, Quillon act on Platinum Equity’s India PE debut

by Nimitt Dixit |

Trilegal and Latham & Watkins have advised U.S.-based buyout fund Platinum Equity on its debut private equity deal in India, in the form of the acquisition of a majority stake in Inventia Healthcare, a Mumbai-based pharmaceutical company, at a valuation of $300 million.